Following Brexit, the United Kingdom’s (UK’s) Medicines and Healthcare products Regulatory Agency (MHRA) introduced significant changes to its drug approval process. Initially, the European Commission Decision Reliance Procedure (ECDRP) was implemented on January 1, 2021. This process relied on the European Commission's decision through the centralized procedure, which required a positive opinion from the Committee for Human Medicinal Products (CHMP).
However, a new regulation, the international recognition procedure (IRP), took effect on January 1, 2024, superseding the ECDRP. The IRP aims to facilitate collaboration between the MHRA and trusted regulatory partners to better serve health care professionals and patients in the UK. Under this procedure, applicants who have already obtained authorization for a drug from one of MHRA's specified reference regulators can benefit from expedited approval.
The IRP offers 2 distinct pathways, Recognition A and B, each with varying criteria, guidelines, and timelines of 60 and 110 days, respectively (Figure 1). This streamlined process significantly reduces both the time and financial burden associated with drug approval compared to traditional marketing authorization procedures. Essentially, the IRP relies on the approval granted by the reference regulator following the review of new drug applications (NDAs) or biological license applications (BLAs).1
The implementation of the IRP marks an enhancement in the efficiency and effectiveness of the UK's drug approval process. The details of its benefits, processes, and requirements are discussed below.1
The Need for MHRA to Implement IRP
The marketing approval for an initial drug application is often considered the most challenging task for a pharmaceutical company. To overcome this tedious approval process, the MHRA has implemented a new procedure aimed at expediting approval for products already marketed in Australia, Japan, Canada, Switzerland, Singapore, the US, and the EU.
The IRP benefits health care professionals, patients, and the pharmaceutical sector by reducing time, cost, and labor, making approval possible in just 60 to 110 days (Figure 2). The IRP integrates and simplifies both the Mutual Recognition/Decentralised Reliance Procedure and the ECDRP under one streamlined process.1,2
A Breakthrough Case Study
A new formulation of a pre-filled syringe denosumab at 120 mg (Xgeva, Amgen) for the treatment of bone cell degeneration due to bone metastasis and giant cell tumors of bone in adults was approved on February 29, 2024, through the IRP. This approval serves as motivation for the development of the regulatory pathway for initial drug applications. The application was initially submitted to the European Marketing Authorization on January 25, 2024. Approximately 30 days later, the drug entered the UK market.3
Understanding the IRP
The IRP is a procedure designed to expedite the introduction of new medicines into the UK market. It is open to applicants who have received approval for the 'same product' from one of the specified reference regulator countries mentioned by the MHRA (eg, Australia, Japan, Canada, Switzerland, Singapore, United States, and the European Union). The guidance specifies that “the same product must contain similar qualitative and quantitative substances and be in the same pharmaceutical form, from applicants belonging to the same group of companies or holding licenses.”1
Ensuring Compliance and Streamlining Submission Process
To ensure compliance and streamline the submission process, applicants should:1,4-6
- Obtain a positive opinion from CHMP or Mutual Recognition/Centralised Procedure before filing under IRP.
- Complete an online eligibility form 6 weeks before submission to determine eligibility for recognition A or B.
- Submit applications through the Human Medicines Portal.
- Ensure manufacturing procedures by reference regulators comply with Goods Manufacturing Procedure considerations.
- Complete a nitrosamine risk assessment before IRP approval.
- Be established in the UK or the EU/European economic area.
- Note that a pre-submission meeting is not necessary for submission via IRP, but it can be scheduled upon request.
- Submit electronic Common Technical Document (eCTD) modules 2 to 5 in EU format at portal submission.
Regulatory Specifications for Module 1 Structure
Even though the IRP involves the dossiers of the reference regulator’s submission, this procedure is entirely evaluated by the MHRA for approval under the UK market. Hence, it is evident that module 1 in eCTD structure should be submitted according to UK specific guidelines to the agency.1